NCT01724294终止不适用
Non-interventional, Post-marketing Study to Evaluate the Correlation Between Clinical and Biological Factors and IPI as Prognostic Factors in Patients With DLBCL in First Line Treatment With R-CHOP
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 113
- 主要终点
- Treatment patterns in clinical practice: Number of treatment cycles received
研究概览
简要总结
This multicenter, observational study will evaluate the correlation between clinical and biological factors and International Prognostic Index (IPI) as prognostic factors in patients with diffuse large B-cell lymphoma receiving first-line treatment with MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy. Eligible patients receiving treatment according to standard of care and local guidelines will be followed for the duration of treatment (approximately 8 months) and during 1 year of follow-up.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients, >18 years of age
- •Patients with diagnosed diffuse large B-cell lymphoma in first-line treatment with R-CHOP
排除标准
- •Prior chemotherapy treatment for diffuse large B-cell lymphoma
- •Contra-indications or exclusion criteria according to the Summary of Product Characteristics for MabThera/Rituxan
结局指标
主要结局
Treatment patterns in clinical practice: Number of treatment cycles received
时间窗: approximately 4 years
次要结局
- Response rates(approximately 4 years)
- Safety: Incidence of adverse events(approximately 4 years)
- Event-free survival(approximately 4 years)
研究者
相似试验
已完成
不适用
Lifetech CeraFlex™ Post-Market Surveillance StudyPatent Foramen OvalePatent Ductus ArteriosusAtrial Septal DefectNCT02621528Lifetech Scientific (Shenzhen) Co., Ltd.120
已完成
不适用
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic DrugEpilepsies, PartialNCT01098162UCB Pharma GmbH576
尚未招募
不适用
Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic LeukemiaB-cell Acute Lymphoblastic LeukemiaNCT06450067Juventas Cell Therapy Ltd.200
已完成
不适用
A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in GreeceAdvanced Soft Tissue SarcomaNCT02618122Genesis Pharma S.A.63
已完成
不适用
Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life SettingNon-Hodgkin's LymphomaNCT02199288Hoffmann-La Roche54